LEO Pharma's novel IL-17A/IL-17AR interaction modulator for the oral treatment of psoriasis Sep. 3, 2021 No Comments
Phase II study of SHR-0302 in alopecia areata meets primary efficacy endpoint Aug. 26, 2021 No Comments
Completed phase I studies of ME-3183 pave way for phase II studies in plaque psoriasis Aug. 24, 2021 No Comments
TYK2 inhibitor NDI-034858 enters phase II investigation for plaque psoriasis Aug. 16, 2021 No Comments